ABSTRACT

Introduction  Persons with haemophilia A (PwHA) commonly experience regular bleeding into joints, which may result in joint damage and complications such as degenerative arthritis. Emicizumab has previously demonstrated efficacy in reducing the occurrence of joint bleeds and target joints, along with having a favourable safety profile; however, data on the long-term effects on joint health are lacking. The AOZORA study will evaluate the long-term safety and joint health of paediatric PwHA without factor (F)VIII inhibitors taking emicizumab; here, we report the details of the study protocol and baseline data.

Methods and analysis  AOZORA is a multicentre, open-label, phase IV clinical study in Japan that aims to enrol approximately 30 PwHA aged <12 years without FVIII inhibitors. The primary endpoints include a long-term safety evaluation of adverse events, laboratory test abnormalities and FVIII inhibitor development; and a long-term joint health assessment using MRI and the Hemophilia Joint Health Score. Exploratory endpoints include characterising participants’ physical activities and the number of activity-related bleeds requiring coagulation factor treatment. Currently, 30 participants have been enrolled, including 20 emicizumab-naïve participants and 10 who transferred from HOHOEMI, a previous study in paediatric PwHA.

Ethics and dissemination  The AOZORA study was approved by the Institutional Review Boards of Nara Medical University and the St Marianna University Group. The study will be conducted in compliance with the Declaration of Helsinki, the standards stipulated in paragraph 3 of Article 14 and Article 80-2 of the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act, the Ministerial Ordinance on Good Clinical Practice and the Ministerial Ordinance on Good Post-marketing Study Practice. Data will be published in peer-reviewed journals and presented at Global congresses.

Trial registration number  JapicCTI-194701.

STRENGTHS AND LIMITATIONS OF THIS STUDY

⇒ AOZORA is a multicentre, open-label, phase IV clinical study with a planned long-term follow-up period of 6 years.
⇒ A sample size of 30 participants was selected based on feasibility and the minimum number of persons with haemophilia A required to assess the long-term effects of emicizumab on joints.
⇒ Although MRI for children can be difficult due to the need for sedation, this mode of imaging is known to be effective for early detection of arthropathy and both reversible and irreversible changes can be evaluated.
⇒ A limitation of AOZORA is that it is a single-arm study, which makes it difficult to evaluate the isolated effect of the study treatment compared with the effect of the disorder’s natural history.

INTRODUCTION

Haemophilia A (HA) is caused by a deficiency in factor (F)VIII; persons with HA (PwHA) experience regular bleeding, most commonly into joints and muscles.1 2 Frequent bleeding into joints may result in joint damage and complications such as degenerative arthritis.3 4 Treatment for HA traditionally consists of intravenous infusions of FVIII multiple times per week.4 5 FVIII prophylaxis has demonstrated significant reductions in joint bleed rates compared with on-demand FVIII treatment; however, even with regular FVIII prophylaxis, bleeding can still occur.6 7 Emicizumab is a bispecific monoclonal antibody that bridges activated FIX(a) and FX, restoring haemostasis.8 9 Emicizumab is administered subcutaneously, once every week, every 2 weeks or every 4 weeks (QW,
Overall, emicizumab had a favourable safety profile.1, 12 Thrombotic microangiopathies (TMAs), thromboembolic torsions, 53.8% of 13 participants had no bleeding events. No deaths occurred with emicizumab in paediatric PwHA without FVIII inhibitors. In the phase III HOHOEMI study two participants who had three and five target joints at baseline, respectively. In the phase III HAVEN clinical programme9 11–13 and studies performed in Japan.1 14 15 In the HAVEN 2 study, emicizumab resulted in a low annualised bleeding rate for treated bleeds (0.3, 95% CI 0.17 to 0.50) in 65 paediatric PwHA with FVIII inhibitors, with 76.9% of participants having no treated bleeding events. In the 23 participants who had received emicizumab for ≥52 weeks, and who had target joints at baseline, all 45 evaluable target joints resolved during the study period.12 Furthermore, twenty of the 23 participants (87.0%) had no target joint bleeds while receiving emicizumab, including two participants who had three and five target joints at baseline, respectively.12 In the phase III HOHOEMI study of emicizumab in paediatric PwHA without FVIII inhibitors, 53.8% of 13 participants had no bleeding events. No thrombotic microangiopathies (TMAs), thromboembolic events (TEs) or fatalities were reported in either study. Overall, emicizumab had a favourable safety profile.1, 12

Despite extensive evidence on the efficacy and safety of emicizumab, there is a lack of data regarding the long-term joint health effects in PwHA. MRI is currently considered to be the most suitable method for early detection of joint disease. The Hemophilia Joint Health Score (HJHS) was developed for joint evaluation in paediatric PwHA and is increasingly being used in this population.

Building on previous paediatric studies, AOZORA (JapicCTI-194701, www.clinicaltrials.jp) was designed to investigate the long-term safety and joint health effects of emicizumab in PwHA aged <12 years without FVIII inhibitors. This manuscript outlines the protocol for the AOZORA study, providing baseline demographic and disease characteristics for enrolled participants.

**METHODS AND ANALYSIS**

**Objectives**

The primary objectives of this study are to evaluate the long-term safety and joint health effects of emicizumab in PwHA <12 years of age without FVIII inhibitors. As an exploratory objective, activities (type and duration) performed by participants receiving emicizumab will be documented, and their association with bleeding events will be assessed.

**Study design and participants**

AOZORA is a multicentre, open-label, phase IV clinical study performed in paediatric PwHA without FVIII inhibitors. Approximately 30 PwHA aged <12 years, without FVIII inhibitors, will be enrolled from 10 centres in Japan. Participants will enter AOZORA either as an emicizumab-naïve participant, or following on from the HOHOEMI phase III study (figure 1).1 Participants from HOHOEMI will continue their emicizumab regimen at one of the three permitted doses.

The study period will be from the date of informed consent, or start of screening of the first participant, to the date of study completion by all participants. The first participant was enrolled on 13 May 2019 and the study is expected to extend to July 2027.

**Eligibility criteria**

Eligibility criteria have been designed to exclude PwHA at higher risk for toxicities. Emicizumab-associated risks include injection-site reactions; acute systemic hypersensitivity reactions, including anaphylaxis and anaphylactoid reactions; TEs and TMAs.

To be included in this study, participants will be aged <12 years, weigh >3 kg, have a diagnosis of severe (endogenous FVIII level <1%) congenital HA and have negative results for FVIII inhibitors within 8 weeks prior to enrolment. All participants must have written consent provided by their legal representative and be able to comply with the scheduled study visits, treatment plans, laboratory tests and other procedures.

Key exclusion criteria include: an inherited or acquired bleeding disorder other than HA, currently undergoing immune tolerance induction therapy, previous or current treatment for signs of thromboembolic disease, prior receipt of emicizumab (participants transferring from HOHOEMI were exempt from this criterion), or currently receiving an investigational drug to treat HA. A full list of eligibility criteria is provided in table 1.

**Patient and public involvement**

There was no patient or public involvement in the design and conduct of this study.

**Interventions and study procedures**

Emicizumab will be administered subcutaneously as one of three approved regimens: 1.5 mg/kg QW, 3.0 mg/kg Q2W or 6.0 mg/kg emicizumab Q4W. Dose selection is to be made at the discretion of the treating physician and will not be influenced by study participation.
Emicizumab-naïve participants will be initiated on a 3 mg/kg loading dose QW for 4 weeks, then will commence with one of the approved regimens. Participants transferring from HOHOEMI will continue on their current dosing regimen; however, the dose can be adjusted from among the approved maintenance regimens. Modifications to emicizumab dosing can be made only by Investigators at the site. Participants will receive emicizumab for 313 weeks from the time of their first injection (for those who transfer from HOHOEMI, this is the first injection during HOHOEMI).

In those participants previously receiving FVIII prophylaxis, administration may continue, to reduce the risk of bleeding, until the day before the second dose of emicizumab. Participants may receive short-term FVIII prophylaxis in anticipation of a surgery-related bleed, or when an unexpected event occurs. FVIII products may be used episodically to treat bleeds that require treatment. The decision to administer FVIII products concomitantly with study treatment, and the dose used, will be at the discretion of the treating physician, as emicizumab will increase the clotting ability. Additional authorised concomitant medications include drugs used to manage adverse events (AEs); topical and local drugs that do not result in systemic exposure, such as topical antiseptics, local anaesthetic and eye-drops; topical anaesthetic creams used collectively with emicizumab injections; sedatives used with MRI scans; and vaccinations. Prohibited concomitant treatments include other investigational drugs, regular FVIII prophylaxis (except the aforementioned) and situational prophylaxis (such as for bleeding prevention before sports and rehabilitation activities).

Baseline measurements will include body weight, physical examination, concomitant medication(s), survey of activities, MRI of the ankles and knees, and HJH S V.2.1 joint assessment. MRI joint assessments will be performed at the following time points: for emicizumab-naïve participants, weeks 1, 145 and 313 (or early termination); and for HOHOEMI participants, week 1 of the HOHOEMI study, then weeks 145 and 313. HJH S joint assessments will occur at weeks 1, 25, 49, 98 and every 48 weeks thereafter (except week 289), week 145 and week 313 for emicizumab-naïve participants; and weeks 1, 49, 97 and every 48 weeks thereafter (except week 289), week 145 and week 313 for participants from HOHOEMI.

Safety assessments will be performed from week 1 to week 313 for all participants. A safety follow-up visit will be performed 24 weeks after the final dose in participants who discontinue emicizumab; this visit will not be performed for participants who continue emicizumab after the end of the study.

---

**Table 1** AOZORA study inclusion and exclusion criteria

<table>
<thead>
<tr>
<th>Inclusion</th>
<th>Exclusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>◆ Written informed consent for study participation from the PwHA’s legally acceptable representative; where possible, written informed consent from the participant</td>
<td>◆ Inherited or acquired bleeding disorder other than HA</td>
</tr>
<tr>
<td>◆ Aged &lt;12 years at the time of informed consent</td>
<td>◆ Current receipt of ITI therapy</td>
</tr>
<tr>
<td>◆ Body weight of &gt;3 kg</td>
<td>◆ Previous (within the past 12 months) or current treatment for thromboembolic disease</td>
</tr>
<tr>
<td>◆ Ability to comply with scheduled study visits, treatment plans, laboratory tests and other procedures</td>
<td>◆ History of clinically significant hypersensitivity associated with monoclonal antibody therapies</td>
</tr>
<tr>
<td>◆ Caregiver ability to comply with all procedures (eg, completion of questionnaires on bleeds and drugs used)</td>
<td>◆ Prior receipt of emicizumab*</td>
</tr>
<tr>
<td>◆ Diagnosis of severe (endogenous FVIII level &lt;1%) congenital HA</td>
<td>◆ Currently receiving an investigational drug; receipt of an investigational drug to treat or reduce the risk of haemophilic bleeds within five half-lives of last drug administration; or receipt of a non-HA-related investigational drug within the last 30 days or five half-lives</td>
</tr>
<tr>
<td>◆ Negative results for FVIII inhibitors (&lt;0.6 BU/mL) in the most recent assay within 8 weeks prior to enrolment</td>
<td>◆ Any other reason that, in the judgement of the investigator, would render the participant unsuitable for inclusion</td>
</tr>
<tr>
<td>◆ Adequate haematological function at the time of screening (WCC ≥100×10⁹ cells/L, haemoglobin ≥8 g/dL (4.97 mmol/L))</td>
<td>◆ In those participants previously receiving FVIII prophylaxis, administration may continue, to reduce the risk of bleeding, until the day before the second dose of emicizumab. Participants may receive short-term FVIII prophylaxis in anticipation of a surgery-related bleed, or when an unexpected event occurs. FVIII products may be used episodically to treat bleeds that require treatment. The decision to administer FVIII products concomitantly with study treatment, and the dose used, will be at the discretion of the treating physician, as emicizumab will increase the clotting ability. Additional authorised concomitant medications include drugs used to manage adverse events (AEs); topical and local drugs that do not result in systemic exposure, such as topical antiseptics, local anaesthetic and eye-drops; topical anaesthetic creams used collectively with emicizumab injections; sedatives used with MRI scans; and vaccinations. Prohibited concomitant treatments include other investigational drugs, regular FVIII prophylaxis (except the aforementioned) and situational prophylaxis (such as for bleeding prevention before sports and rehabilitation activities). Baseline measurements will include body weight, physical examination, concomitant medication(s), survey of activities, MRI of the ankles and knees, and HJH S V.2.1 joint assessment. MRI joint assessments will be performed at the following time points: for emicizumab-naïve participants, weeks 1, 145 and 313 (or early termination); and for HOHOEMI participants, week 1 of the HOHOEMI study, then weeks 145 and 313. HJH S joint assessments will occur at weeks 1, 25, 49, 98 and every 48 weeks thereafter (except week 289), week 145 and week 313 for emicizumab-naïve participants; and weeks 1, 49, 97 and every 48 weeks thereafter (except week 289), week 145 and week 313 for participants from HOHOEMI. Safety assessments will be performed from week 1 to week 313 for all participants. A safety follow-up visit will be performed 24 weeks after the final dose in participants who discontinue emicizumab; this visit will not be performed for participants who continue emicizumab after the end of the study.</td>
</tr>
</tbody>
</table>

*Participants entering AOZORA from the HOHOEMI study will be exempt from this exclusion criterion.

ALT, alanine transaminase; AST, aspartate transaminase; BU, bethesda units; F, factor; HA, haemophilia A; ITI, immune tolerance induction; PwHA, person with haemophilia A; ULN, upper limit of normal; WCC, white cell count.
Activities will be assessed in treatment-naïve participants only on weeks 1, 5 and 13; and for both groups, weeks 25, 37, 49, 61 (and every 12 weeks thereafter), and week 145. Caregivers will be asked to record the types and durations of physical activities of participants at the scheduled time points (see online supplemental file 1 for the Activities Questionnaire).

The full schedules of assessments for all participants are shown in online supplemental tables 1 and 2.

Endpoints
Primary endpoint
The primary endpoint of assessing the long-term safety of emicizumab in paediatric PwHA will include: AEs, AEs leading to discontinuation of emicizumab, AEs of special interest, physical examination findings, laboratory test abnormalities, and development of FVIII inhibitors. The primary endpoint of evaluating joint health effects of emicizumab will be evaluated by MRI-determined knee and ankle scores, and a total score for elbows, knees, ankles and gait, as determined using HJHS V.2.1.

MRI evaluation will be performed using the International Prophylaxis Study Group (IPSG) MRI scale. Both the left and right elbows, knees and ankles will be assessed using the HJHS. Joint assessments will consider swelling, swelling duration, muscle atrophy, crepitus on motion, flexion loss, extension loss, joint pain and strength.16 18

Exploratory endpoints
Exploratory endpoints will include the number, duration and type of activities and the associated number of activity-related bleeds during emicizumab prophylaxis that require coagulation factor treatment. An event is considered a treated bleed if coagulation factors are administered after the development of signs and symptoms of bleeding (eg, pain and swelling). A single bleeding episode will begin with the first sign of a bleed and end 72 hours after the last coagulation factor infusion. Any injection given to treat the bleed >72 hours after the previous infusion will be considered the first infusion to treat a new bleed at the same location.19

Bleeds will be categorised as any of the following three types: spontaneous, defined as a bleed without an identifiable cause; traumatic, when a participant reports a known or believed reason for the bleed (eg, undertaking strenuous exercise, despite the presence or lack of obvious injury); and procedural/surgical, including haematoma resulting from any surgeries or invasive procedures (eg, tooth extraction, venipuncture, or subcutaneous drug administration) or invasive diagnostic procedures (eg, lumbar puncture, arterial blood gas determination or endoscopy with biopsy). Bleeds from procedures or surgeries will not be counted, but will be recorded in the Bleeding Episode Log. Bleed sites will be categorised as: target joints, defined as a major joint (eg, hip, elbow, wrist, shoulder, knee or ankle) in which at least three bleeds have occurred within the last 24 weeks prior to emicizumab initiation, joints, intramuscular or other.

Data analysis
Statistical hypothesis testing was not used to determine the required sample size of this study. A sample size of 30 participants was selected based on feasibility and the minimum number of PwHA required to assess the long-term effects of emicizumab on joints; the 30 participants include those transferring from HOHOEMI.

Data will be collected via electronic data capture (EDC) through use of electronic case report forms (eCRFs). Study sites will be responsible for data entry into the EDC system, Medidata Classic Rave. Participant-reported and caregiver-reported outcome data (bleeds/drugs used, activities) will be collected using paper questionnaires; the data will be entered into the EDC system by study site staff.

All AEs occurring through to the last observation, the completion of the safety follow-up visit performed 24 weeks after discontinuation of emicizumab, the withdrawal of informed consent, or loss to follow-up, regardless of relationship with emicizumab, should be recorded on the eCRF. A consistent methodology of non-directive questioning will be adopted to prevent prompted answers from participants. The WHO toxicity grading scale will be implemented to assess AE severity. Alternatively, reported AEs that are not specifically listed in the WHO scale will be assessed against the AE severity grading scale (online supplemental table 3). All TE and TMA events should be reported as AEs of special interest, as well as serious AEs if they fulfil the seriousness criteria (online supplemental table 4). Serious AEs are required to be reported by the investigator to the sponsor ≤24 hours after learning of the event.

All deaths that occur during the protocol-specified AE reporting period, regardless of relationship to emicizumab, must be recorded on the AE eCRF page and immediately reported to the sponsor. Death will be considered an outcome and not a distinct event. The event or condition that caused or contributed to the fatal outcome should be recorded as the single medical concept on the eCRF.

No confirmatory hypothesis is proposed. Demographic and baseline characteristics will be summarised using means, SD, medians and ranges for continuous variables and incidences and proportions for categorical variables. The safety analysis set will consist of all participants who receive emicizumab at least once during the study. Safety will be assessed through AEs, laboratory test data, and narrative summaries of the development of FVIII inhibitors. The joint assessment analysis set will consist of all participants who receive emicizumab at least once and have at least one MRI measurement and/or HJHS. Joint assessments will be analysed at week 313 or at study withdrawal, whichever occurs first. The change from baseline will be described for each participant. An independent evaluation committee will assess the MRI images.

The exploratory analyses will include all participants who receive emicizumab at least once. Information on activities (type, duration, number of bleeds), and the number of bleeds requiring treatment with coagulation factors will be summarised. An interim analysis will be
performed to evaluate HJHS and MRI scores when all participants have completed week 145.

**Ethics and dissemination**

The AOZORA study was approved by the Institutional Review Boards of Nara Medical University and the St Marianna University Group. The study will be conducted in compliance with the Declaration of Helsinki, the study protocol, the standards stipulated in Paragraph 3 of Article 14 and Article 80-2 of the Pharmaceuticals, Medical Devices and Other Therapeutic Products Act, the Ministerial Ordinance on Good Clinical Practice and the Ministerial Ordinance on Good Post-marketing Study Practice. Data will be published in peer-reviewed journals and presented at Global congresses.

Written informed consent for participation will be obtained by study staff prior to performing any study-related procedures. Written informed consent from the legal representative and, where possible, assent from paediatric PwHA ≥3 years old will be obtained. Each participant will be assigned a unique identification number to maintain patient confidentiality.

**DISCUSSION**

The AOZORA study will evaluate the long-term joint health of paediatric PwHA without FVIII inhibitors receiving emicizumab prophylaxis, an area that requires further research. Currently, 30 participants have been enrolled, including 20 emicizumab-naive participants and 10 who transferred from HOHOEMI (online supplemental figure 1 and online supplemental table 5).

Previous trials in adolescent and adult PwHA without FVIII inhibitors have demonstrated the safety and efficacy of emicizumab. The HOHOEMI study evaluated the rate of joint bleeds in a paediatric population of PwHA without FVIII inhibitors; however, the long-term effects of bleeding on joint health were not assessed.1

In PwHA, haemarthrosis typically occurs before 2 years of age.20 If inadequately treated, these individuals will develop haemophilic arthropathy by 20 years of age.21 At baseline in this study, 12 (41.4%) of the 29 participants with evaluable MRI data displayed pathological changes of knee and/or ankle joints at baseline (positive IPSG score), including two of the six participants aged <2 years (online supplemental figure 2). Although MRI for children can be difficult due to the need for sedation, this mode of imaging is known to be effective for early detection of arthropathy and both reversible and irreversible changes can be evaluated.17

The baseline MRI data demonstrated effusion/haemarthrosis in 18.1% of evaluable joints, while synovial hypertrophy and haemosiderin deposits were each identified in 8.6% of joints (online supplemental table 6). In a recent study, synovial MRI changes, including synovial hypertrophy and haemosiderin deposits, were a strong predictor of joint bleeding and progression of arthropathy in persons with haemophilia, although effusion was not.22 This highlights the importance of identifying early changes to joints.

Use of MRI at multiple time points in AOZORA will enable assessment of how IPSG scores change over time. There are a number of studies evaluating joint health in paediatric PwHA receiving FVIII prophylaxis.23–25 Since the half-life of emicizumab is longer than that of FVIII concentrates,26,27 microbleeding may be suppressed and joint health retained. Emicizumab prophylaxis, therefore, might maintain or improve MRI IPSG scores. No association between treated bleeding and pathological changes were evident in these baseline data. While only two participants reported a treated joint bleed in the 24 weeks prior to enrolment, 12 demonstrated pathological changes at baseline, suggesting that asymptomatic bleeding may affect joint health. As bleeds are treated according to subjective assessment of symptoms by the PwHA or their caregiver, a more objective assessment would be required to fully evaluate the association between bleeding and joint health.

A limitation of AOZORA is that it is a single-arm study, which makes it difficult to evaluate the isolated effect of the study treatment compared with the effect of the disorder’s natural history.26 The study will also not include any significance testing for comparison with previous treatment, and will solely evaluate emicizumab. A further limitation of this study is the small sample size, which is planned to be 30 participants; however, this is similar to the number of participants in other HA clinical trials.27 Furthermore, recruitment of paediatric participants to clinical trials is difficult due to the requirement for consent from a parent or legal representative, assent from the child, and school attendance and parental availability.28

**Author affiliations**

1Department of Pediatrics, Nara Medical University, Kashihara, Japan
2Department of Joint Surgery, IMSUT Hospital, The University of Tokyo, Tokyo, Japan
3Department of Radiology, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
4Department of Pediatrics, St Marianna University School of Medicine, Kawasaki, Kanagawa, Japan
5Division of Hematology, National Center for Child Health and Development, Tokyo, Japan
6Department of Blood Coagulation, Olgikubo Hospital, Tokyo, Japan
7Medical Affairs Division, Chugai Pharmaceutical Co., Ltd., Tokyo, Japan
8Clinical Development Division, Chugai Pharmaceutical Co., Ltd, Tokyo, Japan

**Acknowledgements** The authors would like to thank Akiko Matsuasaki, Mariko Hoshiba and Ryota Kobayashi, all of whom are employees of Chugai Pharmaceutical Co., Ltd, for their contributions to clinical operation; the study participants and their families; and the study investigators, research coordinators and nurses. Medical writing support for the development of this manuscript, under the direction of the authors, was provided by Jacob Watson, BSc, and Katie Smith, PhD, of Ashfield MedComms, an Ashfield Health company, and funded by F. Hoffmann-La Roche Ltd. and Chugai Pharmaceutical Co., Ltd.

**Contributors** MS, MT, AI, HY-S, YK, SY and KN contributed to study design. MS, AI, HY-S, YK and KN contributed to study conduct. MT, AI, AN and KN contributed to recruitment and follow-up of patients. MS, HT, KK, AN, HY-S, YK and KN contributed to data analysis and interpretation. All authors revised the manuscript critically and provided final approval of the version to be published. All authors agreed to be accountable for all aspects of the work.

**Funding** The study was funded by Chugai Pharmaceutical Co., Ltd.

**Competing interests** MS received research funding from Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Sanofi K.K., Bayer AG, Novo Nordisk, BioMarin, KM
Biologics, Takeda, Pfizer, Sekisui Medical, Daiichi Sankyo, and Teijin Pharma; payment for lectures on speaker’s bureau from Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Sanofi K.K., Bayer AG, Novo Nordisk, Takeda, and Pfizer; of which, honoraria payment was received from Chugai Pharmaceutical Co., Ltd.; and holds patents, royalties or other intellectual property with, and receives consulting fees from Chugai Pharmaceutical Co., Ltd. HT received payment for lectures on speaker’s bureau by Chugai Pharmaceutical Co., Ltd., Bayer AG, Biogen, Biocerevit, CSL Behring K.K., Takeda, Novo Nordisk and Pfizer; of which, honoraria or consultation fees were received from Chugai Pharmaceutical Co., Ltd., Bayer AG, CSL Behring K.K., and Novo Nordisk; and expert testimony from Chugai Pharmaceutical Co., Ltd. KK received payment for lectures on speaker’s bureau from Chugai Pharmaceutical Co., Ltd., and CSL Behring K.K.; and expert testimony was received from Chugai Pharmaceutical Co., Ltd. MT received research funding from Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Sanofi K.K., and Novo Nordisk; honoraria or consultation fees were received from Chugai Pharmaceutical Co., Ltd., Bayer AG, CSL Behring K.K., Pfizer, Sanofi K.K., and Takeda and Novo Nordisk. AI received research funding from Chugai Pharmaceutical Co., Ltd., Novo Nordisk, and Pfizer; honoraria or consulting fees were received from Chugai Pharmaceutical Co., Ltd., Pfizer, and Bayer AG; and payment for lectures on speaker’s bureau from Chugai Pharmaceutical Co., Ltd. AN received payment for lectures on speaker’s bureau from Sanofi K.K., Takeda, Chugai Pharmaceutical Co., Ltd., Bayer AG, Fuji Yakuhin, JB, and CSL Behring K.K.; honoraria or consulting fees were received from Takeda, Bayer AG, Fuji Yakuhin, and Chugai Pharmaceutical Co., Ltd. HY-S, YK, and SY are all employees of Chugai Pharmaceutical Co., Ltd. KN received research funding from Chugai Pharmaceutical Co., Ltd., Takeda (Shire) Plc, Sanofi K.K., Novo Nordisk, Bayer AG, and CSL Behring K.K.; consulting fees from Chugai Pharmaceutical Co., Ltd.; and payment for lectures on speaker’s bureau from Chugai Pharmaceutical Co., Ltd., Takeda (Shire) Plc, Sanofi K.K., Novo Nordisk, Bayer AG and CSL Behring K.K.

**Patient and public involvement**

Patients and/or the public were not involved in the design, conduct, or reporting, or dissemination plans of this research.

**Patient consent for publication**

Not applicable.

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Supplemental material**

This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access**

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

**Author note**

The current affiliation of Dr Kaoru Kitsukawa is Radiological Department, Chiba University Hospital, Chiba, Japan.

**ORCID iDs**

Midori Shima http://orcid.org/0000-0002-3922-7061
Hideyuki Takedani http://orcid.org/0000-0001-7707-4778
Kaoru Kitsukawa http://orcid.org/0000-0003-0559-8366
Akira Ishiguro http://orcid.org/0000-0002-3896-5313
Azusa Nagao http://orcid.org/0000-0002-1126-1498
Keiji Nagami http://orcid.org/0000-0002-2415-2194

**REFERENCES**